POET Technologies: From $503,000 in Revenue to a $500 Million Vision — What’s at Stake in June

POET Technologies posts $503K Q1 sales, double year-over-year, as securities lawsuit and PFIC concerns overshadow $400M capital raise for AI photonics.

POET Technologies generated just $503,000 in sales during the first quarter of 2026. That figure, while double the $167,000 reported a year earlier, sits in stark contrast to the multi-hundred-million-dollar ambitions that have driven the stock to a 238% gain over the past twelve months. The disconnect between current reality and future promise is where the real tension lies — and it is about to come to a head.

The company’s rally was ignited in May by a $50 million purchase order from Lumilens for its electrical-optical interposer engines. If development and production milestones are met, the relationship could expand to more than $500 million over five years. That contract positions POET as a supplier to the AI infrastructure boom, with wafer-level photonic integration increasingly critical for data transmission in hyperscale data centers.

Yet the stock has already given back some ground. At €12.96, the shares trade nearly 49% above their 50-day moving average but remain roughly 31% below the 52-week high of €18.84. The relative strength index of 36.9 suggests sentiment has cooled after a recent selloff. Annualized 30-day volatility stands at over 260%, underscoring the speculative nature of the bet.

Legal storm clouds gather

A securities class-action lawsuit filed against POET casts a long shadow over the narrative. The case centers on allegations that the company and its top executives — CEO Suresh Venkatesan and CFO Thomas Mika — made misleading statements about its business operations and financial stability between April 1 and April 27, 2026. Multiple law firms, including Bernstein Liebhard and Faruqi & Faruqi, have reminded investors that they have until June 29, 2026, to apply for lead plaintiff status.

The allegations relate to a sudden breakdown in relations with Celestial AI, a customer that has since been acquired by Marvell Technology. According to the lawsuit, Celestial AI canceled purchase orders after POET violated confidentiality obligations linked to an executive interview. When the termination was disclosed on April 27, the stock plunged about 47% in a single session, sparking the legal action.

Adding to the regulatory uncertainty is POET’s status as a Passive Foreign Investment Company, a designation that carries adverse tax consequences for U.S. investors. Critics say the company failed to provide timely and clear disclosures on the issue. Management aims to resolve the PFIC problem by relocating the corporate domicile from Canada to the United States. Shareholders will vote on the move on June 26, 2026. If approved, the PFIC status would fall away, and POET’s legal home would shift closer to its primary trading venue.

Fresh capital, aggressive targets

Despite the legal distractions, POET has been actively strengthening its balance sheet. In mid-May, it completed a registered direct placement of roughly 19 million new shares to an institutional investor, raising $400 million in gross proceeds. The price of $21.00 per unit represented a premium to the market at the time of the agreement.

Management plans to channel the funds into a dramatic expansion of manufacturing capacity. The goal is to increase wafer production and assembly capacity for optical engines tenfold by 2027. Additional capital will fuel growth in the company’s light-source business and potential acquisitions, as well as general working capital. POET posted a net loss of $12.3 million in the first quarter.

Operational leadership is also evolving. Dr. Sandeep Kumar was named chief operating officer on May 12, signaling a greater emphasis on moving from research toward volume production. Meanwhile, CFO Thomas Mika has announced his intention to retire once a successor is appointed.

A month of converging deadlines

The next two weeks will be critical for POET. The shareholder vote on the US relocation takes place on June 26. Just three days later, on June 29, the window for investors to petition for lead plaintiff status in the securities case closes. In between, the market will watch for any signs that revenue is beginning to close the gap with the valuation implied by the Lumilens framework.

For now, POET remains a story of two halves: a well-capitalized company with a credible $500 million revenue pathway and a legal dispute that threatens to undermine trust. The June events will not resolve the narrative entirely, but they will determine which side of that equation investors focus on in the months ahead.